NYSE: $LLY The Next Generation of Diabetes and Obesity Treatment A recent clinical trial has sent waves through the medical community, showcasing promising results for Eli Lilly’s experimental drug, retatrutide. As the landscape for metabolic health evolves, this new “triple-hormone” receptor agonist is showing potential to outperform current market leaders like Ozempic. Understanding the Clinical…